July 2019
Volume 60, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2019
iNOS-inhibitor treatment leads to cell rescue in a porcine retina organ culture model
Author Affiliations & Notes
  • Jose Hurst
    Research, Eye Hospital Tuebingen, T�bingen, Germany
  • Ana Maliha
    Experimental Eye Research Institute, Ruhr-University Bochum,, Germany
  • Sandra Kuehn
    Experimental Eye Research Institute, Ruhr-University Bochum,, Germany
  • Fenja Herms
    Experimental Eye Research Institute, Ruhr-University Bochum,, Germany
  • Sven Schnichels
    Research, Eye Hospital Tuebingen, T�bingen, Germany
  • Stephanie C Joachim
    Experimental Eye Research Institute, Ruhr-University Bochum,, Germany
  • Footnotes
    Commercial Relationships   Jose Hurst, None; Ana Maliha, None; Sandra Kuehn, None; Fenja Herms, None; Sven Schnichels, None; Stephanie Joachim, None
  • Footnotes
    Support  Set Foundation
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 4873. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jose Hurst, Ana Maliha, Sandra Kuehn, Fenja Herms, Sven Schnichels, Stephanie C Joachim; iNOS-inhibitor treatment leads to cell rescue in a porcine retina organ culture model. Invest. Ophthalmol. Vis. Sci. 2019;60(9):4873.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Nitrite oxide (NO) plays an important role in the pathogenesis of various retinal diseases, especially when hypoxic processes are involved. This degeneration process can be simulated by incubating porcine retinal explants with cobalt-chloride (CoCl2). Based on this model, therapeutic approaches can be tested. Hence, treatment with the iNOS-inhibitor 1400W as a possible protectant was evaluated.

Methods : Explants of porcine retinae were cultivated for 4 and 8 days. Degeneration through 300µM CoCl2 (for 48h) and treatment with the iNOS-inhibitor 1400W (for 72h) were applied simultaneously from day one. Three groups were compared: control, CoCl2, and CoCl2+iNOS-inhibitor. At days 4 and 8, retinal ganglion cells (RGCs), bipolar and amacrine cells were analyzed via immunohistology and qRT-PCR. Furthermore, the influence on the glia cells and different markers (HIF1α, HSP70, iNOS) involved in hypoxic/stress processes were evaluated.

Results : Treatment with CoCl2 resulted in a significant loss of RGCs already after 4 days (Co: 40.0±1.0 RBPMS+cells/mm; CoCl2: 25.7±2.5 RBPMS+cells/mm; p=0.0002), which was counteracted by the iNOS-inhibitor (33.9±2.2 RBPMS+cells/mm; p=0.021). After 8 days the CoCl2 group displayed a significant loss in amacrine cells (Co: 17.7±3.5 calretinin+cells/mm; CoCl2: 3.4±0.5 calretinin+cells/mm; p=0.0003) and downregulation of PVALB mRNA expression (2.8-fold; p<0.05). A drastic reduction in bipolar cells was observed after 8 days (Co: 59.2±2.4 PCKα+cells/mm; CoCl2: 17.1±4.7 PCKα+cells/mm p=0.0001), which was prevented by 1400W (45.4±7.1 PCKα+cells/mm p=0.001). A significant decrease of Iba+ microglia (p=0.0001) and the corresponding mRNA marker was found in the CoCl2 group after 4 and 8 days, which could not be prevented by the iNOS-inhibitor. CoCl2 induced a significant increase in the mRNA expression of HSP70 (5-fold; p=0.008), HIF1α and iNOS (4.5-fold; p-p=0.045). Again, this effect was counteracted by the iNOS-inhibitor.

Conclusions : CoCl2 induces strong degeneration in porcine retinae by mimicking hypoxia, damaging RGCs, amacrine, bipolar and microglia cells. Treatment with the iNOS-inhibitor counteracted these effects to some extent and clearly prevented the loss of retinal ganglion and bipolar cells. Hence, the iNOS-inhibitor 1400W seems to be a very promising treatment for retinal diseases.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×